Hologic’s HOLX acquisition of Biotheranostics in 2021 accelerated its entry into a large, fast-growing oncology adjacency. The business also carries higher margins than the company’s legacy service ...
A new study shows Signatera ctDNA testing may identify older patients with ER+/HER2- breast cancer who can manage their care ...
bioTheranostics, Inc's Breast Cancer Index, a genomic test quantifying the risk of breast cancer recurrence and predicting which patients will likely benefit from extended endocrine therapy, will be ...
Radiologic surveillance of nonfunctional pituitary adenomas provided only minimal benefits for patients with multiple ...
Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial. Rate of medical ...
For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, ...
New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration Findings from 11 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results